Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
52 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Keloids - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Keloids - Pipeline Review, H2 2014', provides an overview of the Keloids's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Keloids - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Keloids - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Keloids Overview 6 Therapeutics Development 7 Pipeline Products for Keloids - Overview 7 Pipeline Products for Keloids - Comparative Analysis 8 Keloids - Therapeutics under Development by Companies 9 Keloids - Therapeutics under Investigation by Universities/Institutes 10 Keloids - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Keloids - Products under Development by Companies 13 Keloids - Products under Investigation by Universities/Institutes 14 Keloids - Companies Involved in Therapeutics Development 15 Paloma Pharmaceuticals, Inc. 15 RXi Pharmaceuticals Corporation 16 vida therapeutics inc. 17 Keloids - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 RXI-109 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 CIGB-128 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 P-529 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CM-101 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 V-2248 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Psoriasin - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Protein for Hypertrophic Scars and keloids - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Keloids - Recent Pipeline Updates 39 Keloids - Dormant Projects 44 Keloids - Discontinued Products 45 Keloids - Product Development Milestones 46 Featured News & Press Releases 46 Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 46 Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 46 Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 47 Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 48 Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 48 Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 49 Mar 03, 2010: Capstone To Continue AZX100 Phase II Clinical Trial In Keloid Scarring 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables Number of Products under Development for Keloids, H2 2014 7 Number of Products under Development for Keloids - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Keloids - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 15 Keloids - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 16 Keloids - Pipeline by vida therapeutics inc., H2 2014 17 Assessment by Monotherapy Products, H2 2014 18 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 26 Keloids Therapeutics - Recent Pipeline Updates, H2 2014 39 Keloids - Dormant Projects, H2 2014 44 Keloids - Discontinued Products, H2 2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.